Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siyang Peng

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Current Medical Research and Opinion|September 2, 2017
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiariesSiyang Peng, Kristen A Deger, Anastasia Ustyugova, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 1, 2025
A meta-analysis of diagnostic yield and clinical utility of genome and exome sequencing in pediatric rare and undiagnosed genetic diseasesRajshree Pandey, Noemi Fluetsch Brennan, Kalliopi Trachana, et al.
The American Journal of Cardiology|August 9, 2014
Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroupsAndreas Clemens, Siyang Peng, Sarah Brand, et al.
HIV Clinical Trials|February 7, 2012
Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United StatesLael Cragin, Feng Pan, Siyang Peng, et al.
Frontiers in Immunology|January 9, 2023
The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping reviewSiyang Peng, Yukun Tian, Linghao Meng, et al.
Thrombosis and Haemostasis|August 18, 2012
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectivenessAnuraag R Kansal, Michael Sharma, Carole Bradley-Kennedy, et al.
Complementary Therapies in Medicine|March 8, 2024
Current state of research on exercise for the treatment of myasthenia gravis: A scoping reviewSiyang Peng, Linghao Meng, Ruiying Fang, et al.
Frontiers in Neurology|January 12, 2024
Mapping current trends and hotspots in myasthenia gravis from 2003 to 2022: a bibliometric analysisYukun Tian, Qiqi Shen, Siyang Peng, et al.
Journal of the American Heart Association|June 14, 2022
Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk-Enhancing Factor in the Pooled Cohort Equation: A Cost-Effectiveness Analysis StudyDeo Mujwara, Geoffrey Henno, Stephen T Vernon, et al.
BMC Public Health|July 1, 2020
Improvement of long-term risks of cardiovascular events associated with community-based disease management in Chinese patients of the Xinjiang autonomous region of ChinaYang Li, Cai Minzhang, Ma Minghui, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Current Medical Research and Opinion|September 2, 2017
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiariesSiyang Peng, Kristen A Deger, Anastasia Ustyugova, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 1, 2025
A meta-analysis of diagnostic yield and clinical utility of genome and exome sequencing in pediatric rare and undiagnosed genetic diseasesRajshree Pandey, Noemi Fluetsch Brennan, Kalliopi Trachana, et al.
The American Journal of Cardiology|August 9, 2014
Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroupsAndreas Clemens, Siyang Peng, Sarah Brand, et al.
HIV Clinical Trials|February 7, 2012
Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United StatesLael Cragin, Feng Pan, Siyang Peng, et al.
Frontiers in Immunology|January 9, 2023
The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping reviewSiyang Peng, Yukun Tian, Linghao Meng, et al.
Thrombosis and Haemostasis|August 18, 2012
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectivenessAnuraag R Kansal, Michael Sharma, Carole Bradley-Kennedy, et al.
Complementary Therapies in Medicine|March 8, 2024
Current state of research on exercise for the treatment of myasthenia gravis: A scoping reviewSiyang Peng, Linghao Meng, Ruiying Fang, et al.
Frontiers in Neurology|January 12, 2024
Mapping current trends and hotspots in myasthenia gravis from 2003 to 2022: a bibliometric analysisYukun Tian, Qiqi Shen, Siyang Peng, et al.
Journal of the American Heart Association|June 14, 2022
Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk-Enhancing Factor in the Pooled Cohort Equation: A Cost-Effectiveness Analysis StudyDeo Mujwara, Geoffrey Henno, Stephen T Vernon, et al.
BMC Public Health|July 1, 2020
Improvement of long-term risks of cardiovascular events associated with community-based disease management in Chinese patients of the Xinjiang autonomous region of ChinaYang Li, Cai Minzhang, Ma Minghui, et al.
Pageof 4